Retrospective Survey of Safety of Fourth Dose Pentacel® in Children
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this survey is to collect selected safety data.
Primary Objective:
To collect selected safety data at 6 months following the 4th dose of the Pentacel® series.
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Retrospective |
| Official Title: | Retrospective Safety Survey of Selected Events in the 6 Months Following the 4th Dose of the Pentacel® Vaccination Series in Children |
- Number of Participants Who Had Positive Response to the Solicited Adverse Events Questionnaire Post 4th Dose of the Pentacel® Vaccination Series [ Time Frame: 6 months post 4th dose vaccination ] [ Designated as safety issue: Yes ]
Positive response is a 'Yes' to any of the following questions:
- Has your child been admitted to a hospital?
- Has your child experienced an illness that made you fear for his/her life (life-threatening episode) that required attendance to the Emergency Room or a Physician's office?
- Has your child developed a medical condition that required 3 or more office or emergency room visits for that condition?
- Has your child been diagnosed by a physician as having:
Low blood count or low platelet count? Swelling or redness of the joints? Asthma? Diabetes? Autism?
- Number of Participants Reporting Serious Adverse Events (SAE) Post 4th Dose of the Pentacel® Vaccination Series and Relationship to Study Vaccine. [ Time Frame: 6 Months post 4th dose vaccination ] [ Designated as safety issue: Yes ]
SAE: any untoward medical occurrence with the following outcomes:
- death,
- a life-threatening adverse drug experience (as confirmed by the investigators),
- inpatient hospitalization or prolongation of existing hospitalization,
- a persistent or significant disability/incapacity, or
- a congenital anomaly/birth defect. Medical conditions that required 3 or more office or emergency room visits, and diagnosis by a physician of low blood cell count or low platelet count, swelling or redness of the joints, asthma, diabetes, or autism were also solicited. (MedDRA Version 6.0)
| Enrollment: | 3214 |
| Study Start Date: | September 2003 |
| Study Completion Date: | April 2005 |
| Primary Completion Date: | April 2004 (Final data collection date for primary outcome measure) |
This is a retrospective survey to collect selected safety data at 6 months following the 4th dose of Pentacel® in children residing in the Canadian Province of British Columbia who have received the 4th dose of the Pentacel® series before their 2nd birthday.
Eligibility| Ages Eligible for Study: | 12 Months to 24 Months |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Children residing in the Canadian Province of British Columbia who have received the 4th dose of the Pentacel® series before their 2nd birthday
Inclusion Criteria:
- Children residing in the Canadian Province of British Columbia who have received the 4th dose of the Pentacel® series before their 2nd birthday.
- Written Informed Consent and Telephone consent from the parent(s) or guardian(s).
- Able to comply with the survey procedures.
Exclusion Criteria:
- Fourth dose of the Pentacel® series received on or after the child's 2nd birthday.
Contacts and Locations
More Information
Additional Information:
No publications provided
| Responsible Party: | Medical Monitor, Sanofi Pasteur Inc. |
| ClinicalTrials.gov Identifier: | NCT00772369 History of Changes |
| Other Study ID Numbers: | M5A08 |
| Study First Received: | October 13, 2008 |
| Results First Received: | March 15, 2010 |
| Last Updated: | April 1, 2010 |
| Health Authority: | Canada: Health Canada |
Keywords provided by Sanofi:
|
Pertussis Whooping cough Diphtheria |
Tetanus Haemophilus influenzae Poliovirus Types 1, 2, and 3. |
Additional relevant MeSH terms:
|
Diphtheria Haemophilus Infections Whooping Cough Poliomyelitis Tetanus Tetany Corynebacterium Infections Actinomycetales Infections Gram-Positive Bacterial Infections Bacterial Infections Pasteurellaceae Infections Gram-Negative Bacterial Infections Bordetella Infections Respiratory Tract Infections Infection |
Respiratory Tract Diseases Myelitis Central Nervous System Viral Diseases Virus Diseases Enterovirus Infections Picornaviridae Infections RNA Virus Infections Central Nervous System Infections Central Nervous System Diseases Nervous System Diseases Spinal Cord Diseases Neuromuscular Diseases Clostridium Infections Neuromuscular Manifestations Neurologic Manifestations |
ClinicalTrials.gov processed this record on May 16, 2013